期刊文献+

肺毛霉菌病的诊治进展 被引量:17

下载PDF
导出
摘要 肺毛霉菌病是一种罕见的,但死亡率极高(高达50%以上)的条件致病菌真菌感染。多继发于免疫功能低下以及有糖尿病、恶性血液系统疾病等危险因素的患者。临床表现多为发热、咳嗽,咯血。胸部平片及CT上可表现为渗出,楔形的实变,单侧或双侧结节样病变,孤立或多发肿块,空洞。肺毛霉菌病的诊断主要依靠肺活组织检查,痰培养的假阳性率极高,早期诊断很困难。治疗上主要采用两性霉素B和外科手术治疗。
作者 卫琰 沈策
出处 《临床肺科杂志》 2007年第7期726-727,共2页 Journal of Clinical Pulmonary Medicine
  • 相关文献

参考文献10

  • 1Tedder M,Spratt JA,Anstadt MP,Hegde SS,Tedder SD,Lowe JE.Pulmonary mucormycosis:results of medical and surgical therapy.Ann Thorac Surg,1994,57:1044-1050.
  • 2Lee FY,Mossad SB,Adal KA.Pulmonary mucormycosis:the last 30 years.Arch Intern Med,1999,159:1301-1309.
  • 3Abraham P,Govil S,Srivastava VM,Ganesh A.Sponta-neous regression of pulmonary mucormycosis.Postgrad Med J,1995,71:632 -634.
  • 4侵袭性肺部真菌感染的诊断标准与治疗原则(草案)[J].中华内科杂志,2006,45(8):697-700. 被引量:867
  • 5Pagano L,Ricci P,Tonso A,et al.Mucormycosis in patients with haematological malignancies:a retrospective clinical study of 37 cases.Br J Haematol 1997 ;99:331-336.
  • 6Groll AH,Walsh TJ.Uncommon opportunistic fungi:new nosocomial threats.Clin Microbiol Infect,2001,7:8-24.
  • 7Gomez Lopez A,Cuenca Estrella M,Monzon A,Rodri gnez-Tudela JL.In vitro susceptibilities of clinical isolates of zygomycota to amphotericin B,flucytosine,itracon-azole,and voriconazole.J Antimicrob Chemother,2001,48:919 -921.
  • 8Jose R.Donado Unaa:Persistent cavitations in pulmonary mucormycosis after apparently successful amphotericin B; European Journal of Cardiothoracic Surgery,2002,21:940-942.
  • 9Louie,A,Banerjee P,Drusano GL.et al.Interaction between flucon-azole and amphotericin B in mice with systemic infection due to flucon-azole susceptible or resistant strains of Candida albicans.Antimicrobial Agents and Chemotherapy,1999,43:2841-4847.
  • 10Rodero L,Cordoba S,Cahn P,et al.In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.Journal of Antimicrobial Chemotherapy,2000,45:239-242.

二级参考文献7

  • 1黄晓军.血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(草案)[J].中华内科杂志,2005,44(7):554-556. 被引量:423
  • 2Stevens DA,Kan VL,Judson MA,et al.Practice guidelines for diseases caused by Aspergillus.Infectious Diseases Society of America.Clin Infect Dis,2000,30:696-709.
  • 3Ascioglu S,Rex JH,de Pauw B,et al.Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus.Clin Infect Dis,2002,34:7-14.
  • 4Denning DW,Kibbler CC,Barnes RA,et al.British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections.Lancet Infect Dis,2003,3:230-240.
  • 5Pappas PG,Rex JH,Sobel JD,et al.Guidelines for treatment of candidiasis.Clin Infect Dis,2004,38:161-189.
  • 6Slavin MA,Szer J,Grigg AP,et al.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Intern Med J,2004,34:192-200.
  • 7Saag MS,Graybill RJ,Larsen RA,et al.Practice guidelines for the management of cryptococcal disease.Infectious Diseases Society of America.Clin Infect Dis,2000,30:710-718.

共引文献866

同被引文献76

引证文献17

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部